MSF made the commitment to Apotex that if Apotex developed this drug, this three-in-one fixed-dose combination that they needed in the field, they would seek to purchase it under CAMR from Apotex. Given the way the law is worded, in order for MSF to be able to do that, they needed a country to come forward and notify the WTO of their intention to do this and also of the quantity of the drug that the country expected to need.
On October 21st, 2010. See this statement in context.